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Abstract
MicroRNAs (miRNAs) are small, non-protein-coding RNA molecules that modulate gene translation. Their expression is
altered in many central nervous system (CNS) injuries suggesting a role in the cellular response to stress. Current studies in
brain tissue have not yet described the cell-specific temporal miRNA expression patterns following ischemic injury. In this
study, we analyzed the expression alterations of a set of miRNAs in neurons and astrocytes subjected to 60 minutes of
ischemia and collected at different time-points following this injury. To mimic ischemic conditions and reperfusion in vitro,
cortical primary neuronal and astrocytic cultures prepared from fetal rats were first placed in oxygen and glucose deprived
(OGD) medium for 60 minutes, followed by their transfer into normoxic pre-conditioned medium. Total RNA was extracted
at different time-points after the termination of the ischemic insult and the expression levels of miRNAs were measured. In
neurons exposed to OGD, expression of miR-29b was upregulated 2-fold within 6 h and up to 4-fold at 24 h post-OGD,
whereas induction of miR-21 was upregulated 2-fold after 24 h when compared to expression in neurons under normoxic
conditions. In contrast, in astrocytes, miR-29b and miR-21 were upregulated only after 12 h. MiR-30b, 107, and 137 showed
expression alteration in astrocytes, but not in neurons. Furthermore, we show that expression of miR-29b was significantly
decreased in neurons exposed to Insulin-Like Growth Factor I (IGF-I), a well documented neuroprotectant in ischemic
models. Our study indicates that miRNAs expression is altered in neurons and astrocytes after ischemic injury. Furthermore,
we found that following OGD, specific miRNAs have unique cell-specific temporal expression patterns in CNS. Therefore the
specific role of each miRNA in different intracellular processes in ischemic brain and the relevance of their temporal and
spatial expression patterns warrant further investigation that may lead to novel strategies for therapeutic interventions.
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Introduction
The discovery of microRNAs (miRNAs), a novel class of small
non-protein-coding molecules, has introduced a whole new level
and mechanism of gene regulation[1–5]. Long RNA precursors of
miRNAs are transcribed from the cellular genome and undergo
sequential processing by several RNase complexes to produce
small (18 – 25 nucleotides) mature miRNAs[6]. MiRNAs regulate
gene expression at the post-transcriptional level by altering
translation of target messenger RNAs (mRNAs) into proteins.
The mechanisms by which miRNAs function is by inhibition of
the protein translation or by promotion of mRNA decay[7]. By
targeting the mRNA of protein-coding genes, miRNAs play a
critical role in development, control of cell growth, proliferation,
metabolism and in a variety of other biological processes[6].
MiRNAs have been implicated as well in the etiology of a variety
of pathological processes such as cancer, ischemia, developmental
arrest, inflammatory diseases and cellular response to stressful
conditions [7–37].
Ischemia is an essential feature of Central Nervous System
(CNS) injury in stroke, cancer, traumatic brain injury (TBI) and
spinal cord injury (SCI). Neurons and astrocytes, as other cells
respond to injury by altering their gene and protein expression
patterns[38,39]. Since the first discovery that miRNAs are present
in the CNS[4], several studies have suggested miRNA’s involve-
ment in CNS physiological and pathological processes[1,5,22–
37,40–42]. Expression profiling of miRNA at the tissue level has
been performed in stroke, TBI and SCI. In these studies it has
been reported that miRNAs demonstrate significant expression
level changes, suggesting their implication in the disease
process[32,35,37]. Presently, little is known about the alteration
of miRNAs levels in neuronal and astrocytic response to ischemic
conditions[32]. A better understanding of the molecular mecha-
nisms responsible for the behavior of the different CNS cells
during ischemic injury may lead to novel strategies for cell-specific
therapeutic interventions.
The CNS has different cell types with different roles that react
differently to changes in the surrounding environment. In this
context, miRNA profiling from whole brain tissue cannot relate
expression changes to a certain cell type and distinguish cell-
specific patterns in neurons and astrocytes. This shortcoming of
miRNA profiling experiments from the tissue level can impair our
ability to draw accurate conclusions on miRNA cell-specific
role[43]. Thus, to understand the role of miRNAs in the cerebral
injury, there must first be an understanding of how different
miRNAs behave in different cell types involved in a particular
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patterns differ in astrocytic and neuronal cells in response to
ischemic conditions.
From the current literature, we identified a set of miRNAs that
have been reported to alter their expression pattern during TBI
and stroke at the tissue level. These miRNAs appear to play an
important role during hypoxic stress in other non-cerebral cell
types as well[7,44]. In this study, we compared temporal changes
in expression levels of this set of miRNAs that were induced by
oxygen-glucose deprivation (OGD) in astrocytes and neurons. We
report here that in neurons and astrocytes, miRNAs alter their
expression levels in response to OGD in vitro and that these
alterations are cell-specific. Furthermore, we show that a known
neuroprotectant, Insulin-Like Growth Factor I (IGF-I), can reduce
the expression of miR-29b, which is highly upregulated in
ischemic neurons.
Materials and Methods
Cell cultures
All the animal work was carried out in the animal facility at the
University of Texas Health Science Center in San Antonio
(UTHSCSA) after being approved by the Animal Care and Use
Committee at the UTHSCSA (Protocol Number 07071) and
adhered to the National Institute of Health principles of laboratory
animal care (NIH publication No. 80–23).
Mammalian cortical neurons were grown in dissociated cultures
as previously described[45–47]. Briefly, pregnant Sprague-Dawley
rats, 17 days post conception, were sedated and embryos were
extracted with sterile technique. The brain cortices of the embryos
were removed, and after trypsinization, cells were plated onto
poly-L-lysine coated 35 mm dishes and maintained in serum-free
Neurobasal Medium supplemented with B27 at 37uC, 5% CO2,
in a humidified environment. Astrocyte cultures were isolated from
17 day-old rat embryos as well, and maintained in DMEM
containing 10% bovine calf serum at 37uC, 5% CO2 in a
humidified environment and allowed to grow to confluence.
Astrocytes were then trypsinized and plated onto 60 mm dishes at
a density of 1.5610
4 cells/cm
2 and used when they were
confluent. The purity level of each culture was tested using
immunofluorescent techniques. Cells grown on cover slips were
labeled with a neuronal marker (anti-MAP2, Sigma) and an
astrocyte marker (anti-GFAP, Sigma). Neuronal cultures con-
tained less than 3% of GFAP-positive cells. Astrocytic cultures did
not contain any MAP2-positive cells. Four different litters were
used for each set of experiments to produce an n=4.
Oxygen–glucose deprivation
Cells in culture were placed in oxygen-glucose deprivation
(OGD) conditions as previously described[48]. Briefly, the culture
medium was replaced by a glucose-free Earle’s balanced salt
solution (EBSS) with the following composition: KCl 5 mM,
NaHCO3 26 mM, NaCl 117 mM, NaH2PO4 1 mM, which was
previously saturated with 1% O2, 5% CO2, 94% N2 gas at 37uC
overnight. The cultures were then placed in an airtight incubation
chamber (CBS Scientific) equipped with inlet and outlet valves,
and flushed for 4 minutes with a continuous influx of 1% O2,5 %
CO2, 94% N2 gas at a flow rate of 20 L/minute. The chamber
was then sealed to maintain the gas composition and placed into
an incubator at 37uC for 60 minutes. Afterwards the cultures were
removed from the airtight hypoxic chamber and the glucose-free
EBSS medium was replaced with the pre-OGD conditioned
medium. At 0, 2, 4, 6, 8, 12 and 24 hours after termination of
OGD conditions the cells were collected and RNA extracted.
Control cell cultures were not exposed to OGD. The experiments
were performed in quadruplicate.
MicroRNA collection
RNA was isolated from primary rat cultures that were highly
purified (.98%) for either cerebral cortical neurons, or astrocytes
that had undergone OGD or were maintained under normoxic
conditions as described above. Cells were rinsed in PBS, lysed and
scraped from the culture plates. Total RNA (including miRNAs)
was isolated using the miRVana miRNA isolation kit according to
the manufacturer’s instructions (Ambion, Austin, TX). RNA
quantification and quality assessment was performed by measuring
the ultraviolet absorbance at 260 nm wave-length and the
260 nm/280 nm absorbance ratio in a DU530 spectrophotometer
(Beckman Coulter)[33]. A ratio of 1.8–2.1 was considered
satisfactory[33].
TaqMan RT-PCR
For the quantitative analysis, two-step TaqMan real-time RT-
PCR was performed using TaqMan MicroRNA Reverse Tran-
scription kit (Applied Biosystems) on a 7500HT real-time PCR
instrument (Applied Biosystems). Total RNA was converted into
cDNA by reverse transcriptase (RT) reaction that was performed
by sequential incubation at 16uC for 30 min, 42uC for 30 min,
85uC for 5 min and 4uC. The same amount of RNA for each
sample was added to the RT reaction mix for each miRNA of
interest. The input amount consisted of 10 ng of total RNA for
each 15 mL of RT reaction as recommended by the manufacturer
(Applied Biosystems, Protocol 4364031 Rev. E) and as suggested in
the literature[28,37]. PCR reaction mixture (20 mL) contained
1.33 mL of RT product, 10 mL of TaqMan 2X Universal PCR
Master Mix and 1 mL of the appropriate TaqMan MicroRNA
Assay (20X) containing primers and probe for the miRNA of
interest (Applied Biosystems). The mixture was initially incubated
at 95uC for 10 min, followed by 40 cycles of 95uC for 15 seconds
and 60uC for 60 seconds. Primers for mature miR-21, miR-29b,
miR-30b, miR-107, miR-137 and miR-210 (Applied Biosystems)
were designed using the known mouse sequences from miRNA
database[49–52] at http://www.mirbase.org (Table 1). Analysis
was performed in duplicate with no-template control used as
negative control.
SnoRNA-135, 18S rRNA, snoRNA-202, RN-U6 and human b-
actin RNA were tested as internal controls on neurons and
astrocytes. The expression levels of these small RNAs were altered
in excess of 1.5 fold in at least one time-point (data not shown) in
both neurons and astrocytes. It is a well-known phenomenon that
experimental conditions may alter the expression of genes that are
candidates for internal controls[34,53,54]. Hence, to analyze the
data, we used the method described for these conditions by Livak
and Schmittgen[55] where, after determining the concentration of
RNA by UV absorbance method in a spectrophotometer[55], the
same amount of RNA was converted into cDNA and used for each
RT-PCR experiment. The relative expression of every specific
miRNA for each time-point was compared to that of normoxic
specimen and presented as 2
2DC’T, (where DC’T=C T, Time x –
CT, Control and CT is the cycle threshold)[55,56].
Insulin-Like Growth Factor I (IGF-I)
Recombinant human IGF-I (R&D Systems) was reconstituted at
100 mg/mL in sterile PBS as suggested by the manufacturer.
Normoxic neuronal cultures (35 mm dishes) were treated with
100 ng/mL of IGF-I and changes in miRNA levels were measured
using RT-PCR. We screened the same miRNAs as described
above (miR-21, miR-29b, miR-30b, miR-107, miR-137, miR-
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PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e14724210). Total RNA was isolated from neurons using the miRVana
miRNA isolation kit. Two-step TaqMan real-time RT-PCR was
performed using TaqMan MicroRNA Assays on a 7500 real-time
PCR instrument as described above. All RNA samples were
normalized to an internal control, U6 small nuclear RNA.
Analysis was performed in duplicate, with no-template controls.
Relative expression was calculated using the comparative cycle
threshold method (2
2DDCt)[56]. All data is expressed as the mean
6 the SE (n=3).
Statistical Analysis
Quantitative RT-PCR data were compared by one-way analysis
of variance (ANOVA) followed by Dunnett’s multiple comparison
tests to determine overall significance of fold-changes in miRNA
expression levels compared to control. Mean expression levels for
each miRNA were compared for each time point between neurons
and astrocytes using Student’s t test. For correlation, R-squared
values were calculated using the log of the fold changes in miRNA
levels. P values of ,0.05 were considered to be significantly
different.
Results
We examined temporal changes in expression levels of a specific
set of miRNAs in neurons and astrocytes at 0 h, 2 h, 4 h, 6 h, 8 h,
12 h and 24 h after the OGD as compared to cells growing in
normal conditions (control). We considered a trend of expression
change when expression level was altered more than 1.5-fold, and
strong expression change if altered .2-fold[8]. We chose these
specific miRNAs because they have been shown to alter their
expression levels in several CNS pathologies[31,32,35,37,38].
Furthermore these miRNAs have been reported to be involved in
cell response to hypoxia and are considered to be part of a set
identified as hypoxia-regulated microRNAs (HRMs)[7,8,44].
MiR-21 was upregulated 1.5-fold at 12 h and 1.94-fold
(p,0.05) at 24 h post-OGD as compared to expression in control
neurons. MiR-29b showed the highest expression alteration in
neurons exposed to OGD. It was upregulated by 1.6-fold at 2 h
post-OGD (p,0.05), and 4-fold (p,0.05) at 24 h suggesting a
strong involvement of this miRNA in the neuronal response to
ischemia. MiR-30b, miR-107 and miR-137 did not alter their
expression levels in neurons. MiR-210 was more than 2-fold
upregulated at 12 h and 24 h (Figure 1).
A different pattern of expression for the miRNAs tested was
noticed in astrocytes undergoing OGD (Figure 1). MiR-21 showed
a trend of upregulation (.1.6-fold, p,0.05) only at 12 h post-
OGD. MiR-29b expression was upregulated in astrocytes as well,
but to a lesser magnitude than in neurons. MiR-29b showed a
trend of upregulation at 6 h post-OGD with .1.7-fold increase,
and .2-fold at 12 h post-OGD (p,0.05). MicroRNAs 30b, 107
and 137 in astrocytes expressed a change in their levels post-OGD
conditions. MiR-30b showed a trend of expression change at 6, 8
and 12 h (p,0.05). MiR-107 was upregulated 1.56-fold at 8 h and
1.7-fold at 12 and 24 h (p,0.05). MiR-137 showed a trend of
upregulation after 4 h post-OGD and continued to be upregulated
as well at 6, 8 and 12 h. MiR-210 was upregulated after 6 h by
.1.6-fold and significantly upregulated at 8, 12 and 24 h (p,0.05)
suggesting a strong involvement of this miRNA in astrocytic
response to ischemia (Figure 1).
In our study, we found that there is a poor correlation (R
2
correlation coefficient =0.098) between expression levels of each
specific miRNA in astrocytes and neurons in response to
ischemic conditions at different time-points (Figure 2). While in
neurons undergoing OGD conditions, miR-30b, 107 and 137
did not show any expression alterations, these same miRNAs
showed a significant expression upregulation in astrocytes when
compared to cells in normoxic conditions. MiR-29b is
upregulated in both neurons and astrocytes post-OGD, but at
different time-points and with remarkable difference in magni-
tude. MiR-21 is significantly upregulated at 12 h and 24 h in
astrocytes however in neurons upregulation occurred only after
24 h. MiR-210 is significantly upregulated in astrocytes at 8 h,
12 h and 24 h. In neurons, miR-210 showed a significant
variability between each set of experiments. This might suggest
that miR-210 is tightly controlled in ischemic conditions in
neurons and small changes in experimental conditions may
affect its expression significantly. Unfortunately, no definitive
conclusions could be drawn for miR-210 involvement in neurons
exposed to OGD.
A direct comparison of expression levels of all the miRNAs used
for our study between neurons and astrocytes undergoing OGD
conditions, showed a significant difference at different time-points
only for miR-29b, miR-30b, miR-107 and miR-137 (Figure 1).
IGF-I has been shown to be neuroprotective in a number of
ischemic models[47,57–59]. We wanted to determine if a
neuroprotectant, such as IGF-I, could effect the expression of
miRNAs that are known to be altered under ischemic conditions.
Therefore, neuronal cultures were exposed to IGF-I (100 ng/mL)
for 24 h and changes in miRNA levels were measured at various
time points using RT-PCR. We screened the same miRNAs as
described above (miR-21, miR-29b, miR-30b, miR-107, miR-137,
miR-210) and found that IGF-I significantly decreases the
expression of mir-29b in neurons. Compared to control (0 h),
miR-29b was decreased -2.8-fold at 8 h and was further decreases
by -3.3-fold at 24 h (Figure 3). IGF-I did not have an effect on the
expression levels of mir-21, mir-30b, mir-107, mir-137, or mir-210
in neurons.
Table 1. The Sequences of the Primers for miRNAs used.
miRNA name Identification Accession Number Primers Sequence
miR-21 mmu-miR-21 MIMAT0000530 TAGCTTATCAGACTGATGTTGA
miR-210 mmu-miR-210 MIMAT0000658 CTGTGCGTGTGACAGCGGCTGA
miR-137 mmu-miR-137 MIMAT0000149 TTATTGCTTAAGAATACGCGTAG
miR-29b mmu-miR-29b MIMAT0000127 TAGCACCATTTGAAATCAGTGTT
miR-30b mmu-miR-30b MIMAT0000130 TGTAAACATCCTACACTCAGCT
miR-107 mmu-miR-107 MIMAT0000647 AGCAGCATTGTACAGGGCTATCA
Sequences were reviewed on miRNA database[49–52,83] at http://www.mirbase.org.
doi:10.1371/journal.pone.0014724.t001
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neurons or astrocytes that had undergone OGD (1 h) or were maintained in normoxic conditions. RNA concentrations were determined by UV
absorbance, and 10 ng for each sample was converted into cDNA and expression levels were measured using RT-PCR[55]. The fold-change in
expression of each miRNA compared to that of the normoxic specimen was calculated using 2
2DC’T formula. Data is expressed as the mean 6 the SE
(n=4). The results were analyzed by one-way ANOVA followed by multiple comparisons test (* p,0.05, normoxia versus OGD within each cell type).
Differences in the mean expression level for each miRNA between the two different cell types was compared for each time point post-OGD by
Student’s t test (# p,0.05, astrocyte versus neuron).
doi:10.1371/journal.pone.0014724.g001
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It is believed that multiple post-transcriptional mechanisms play
an important role in the regulation of gene expression[60]. It is
becoming widely accepted that miRNAs are an important part of
these regulatory pathways[1,9,25,30,32,33,37,60–63].
Ischemia is a hallmark of cellular stress and is considered one of
the major culprits of CNS injury in many pathological processes. It
has been suggested that miRNAs play an important role in cellular
response to hypoxic stress[8,12,64,65]. Kulshreshtha and col-
leagues[12] have identified a set of hypoxia-regulated microRNAs
(HRM) in tumor cells, providing an additional link between
tumor-specific stress factors and gene expression control. Further-
more, miRNAs have been shown to change their expression levels
in myocardiocytes during ischemic stress[66]. It has been recently
reported that expression of miRNAs is altered in the injured CNS
tissue following stroke, TBI and SCI[32–35,37]. To our
knowledge the relation between cell-specific temporal changes in
expression levels of miRNAs and hypoxia in vitro has not been
reported in neurons and astrocytes.
Our study demonstrates that expression levels of miRNAs
change when neurons and astrocytes are subjected to OGD,
suggesting miRNA involvement in the cellular response to
ischemia in these cells. Furthermore we show that miRNA
temporal expression alterations in response to OGD are different
in astrocytes and neurons. We found that immediately after 60
minutes of ischemia (time 0 in our experiments), none of the
miRNAs studied demonstrated a change in their expression levels
in neither cell type (Figure 1). Three possible explanations could be
considered: First, after 60 min of OGD, neurons and astrocytes
may utilize the remaining resources for basic cell-survival needs
and not in activation and transcription of miRNAs, and gene
translation into proteins. Second, it could be that synthesis of
miRNAs is a later event in the hypoxic cascade of these cells
response to ischemia. Lastly, other miRNAs may be involved in
the early response of neurons and astrocytes to ischemia, and the
miRNAs studied here are involved at later time – points. At 2 h,
we saw a trend of upregulation of miR-29b in neurons that steadily
increased up to 4-fold at 24 h. In contrast, in astrocytes, miR-29b
showed a trend of upregulation later, after 6 h and a significant
level increase by 2-fold only after 12 h. MiR-30b, miR-107 and
miR-137 were uniquely upregulated only in astrocytes at different
time-points, starting 6 h after OGD event. MiR-210 showed a
trend of upregulation after 6 h and a significant upregulation after
8 h in astrocytes (Figure 1). MiR-21 showed a similar expression
alteration in neurons and astrocytes. MiR-29b, miR-30b, miR-107
and miR-137 showed a significant difference in their expression
levels between neurons and astrocytes undergoing OGD condi-
tions (Figure 1). Furthermore, from our experiments, we
discovered that the 6 h mark appears to be important for different
Figure 2. MicroRNAs express different alteration patterns in neuron and astrocytes undergoing OGD conditions. Each data point
represents the average log of fold changes of a particular miRNA at different time-points in neurons and astrocytes from 4 independent experiments.
Note that there is a very poor correlation (R
2 correlation coefficient =0.098) between the miRNAs expressions in neurons and astrocytes at different
time-points post-OGD.
doi:10.1371/journal.pone.0014724.g002
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after ischemic injury.
Wang and colleagues[67] have shown that there is a difference
in the miRNA repertoire between superficial white matter and
overlying gray matter in humans. In our study, we demonstrate
that OGD induces miRNA expression in a cell-specific pattern at
different time-points in astrocytes and neurons. We speculate that
this could be secondary to the difference in the baseline cell
specific repertoire of miRNAs, or considering their role and
function in the global physiology of the brain, astrocytes and
neurons activate different biochemical pathways after ischemia
and hence different miRNAs are expressed in each cell type.
MiRNAs modulate gene expression at the posttranscriptional
level and can modulate many different cellular and pathological
processes by fine tuning protein expression patterns[35]. It is
thought that ischemia induces genes that cause apoptosis[68].
Demonstrating that astrocytes and neurons express cell specific
changes in miRNA levels after ischemic injury, is a significant step
toward understanding of their involvement in the underlying
molecular mechanisms of cerebral injury. Park and colleagues[69]
have shown that family members of miR-29 upregulate the
expression of p53 through regulation of transcription of cdc42 and
p85a in tumor cells and as such induce apoptosis. Garzon and
colleagues[70] reported that over-expression of synthetic miR-29b
in acute myeloid leukemia (AML) cell lines and primary AML
blasts induced apoptosis. These studies strongly support the idea
that by the blockage or enhancement of miR-29b expression we
could influence apoptosis of cells of interest[69,70]. Control of
neuronal apoptosis after ischemia is important when considering
that the degree of neurologic disability after CNS hypoxic injury
depends on the extent of neuronal loss. In this study we were able
to show a novel effect of IGF-I, that of suppression of miR-29b
expression in neurons. We speculate that the downregulation of
miR-29b by IGF-I could possibly play a role in the anti-apoptotic
signaling afforded by activation of the IGF-I receptor, but further
studies would be needed in order to substantiate this hypothesis.
Another recent study found that miR-29 family could regulate
DNA methylation via DNA methyltransferase 3A and 3B
transcriptional regulation[71]. Abnormal DNA methylation can
cause cell death and has been documented to be altered in
Alzheimer disease. In addition miR-29a/b was shown to be
involved in BACE-1 expression in patients with Alzheimer’s
disease[31]. Our findings that miR-29b is upregulated in
astrocytes and neurons after ischemia in vitro opens the path for
further investigations to the role of miR-29 in apoptosis in other
forms of dementia that have been related to lacunar brain
ischemia. Hypoxia has been shown to induce the upregulation of
miR-210 in cancer and non-cancer cells[7,12]. Zhang and
colleagues[72] have recently described that miR-210 influences
the hypoxic response in tumor cells through targeting a key
transcriptional repressor of the MYC-MAX network. In our study,
miR-210 is significantly upregulated in astrocytes after 8 h.
While our efforts in neurons are focused on finding those
miRNAs involved in apoptosis after ischemic insult; in astrocytes
it is important to study those miRNAs that may control their
function in protecting the CNS environment after ischemia. It
has been postulated that miRNAs are involved in inflammation
and cell response to free radicals after hypoxia[73]. MiR-21
alteration has been shown to be important in protecting
myocardiocytes against H2O2 radicals after ischemia[74]. MiR-
21 is upregulated in astrocytes 12 h after ischemia, the time when
multiple free radicals are present in ischemic brain. The role of
miR-21 in the cellular response to the free radicals in CNS
warrants further investigation. MiR-107, miR-30 and miR-137
were upregulated only in astrocytes. While it is premature to
anticipate any specific role for these miRNAs in astrocytic
response to ischemic conditions in vitro, few speculations can be
made based on their suggested role in other cellular systems of
recent investigation.
Progranulin/granulin (GRN) is a protein that modulates
inflammation and gliosis. A recent study by Wang and
colleagues[75], indicated that miR-107 contributes to GRN
expression regulation in human H4 neuroglioma cells and a TBI
rat model. It can be speculated that changes in expression levels of
miR-107 in astrocytes after OGD, may modulate inflammation
and gliotic processes in the brain after hypoxic injury through
alteration of GRN expression. It has been reported that miR-137
expression is decreased in astrocytoma cell lines relative to normal
brain tissues[76]. In this study, miR-137 was found to be a direct
inhibitor of CDK6, suggesting a role of this miRNA in
astrocytoma cell proliferation. In light of these results, our findings
that miR-137 level is increased only in astrocytes exposed to
OGD-conditions, suggest that miR-137 may induce astrocytic
proliferation as observed after ischemic stroke[77,78]. To our
knowledge, the role of miR-30 has not been studied in astrocytes.
Recently it was reported that members of miR-30 family are
involved in myocardial extracellular matrix remodeling targeting
connective tissue growth factors that are induced by TGF-b and
endothelin[79]. It is known that TGF-b and endothelin-1 regulate
astrocyte proliferation and reactive gliosis as well [80,81]. It is
tempting to speculate a role of miR-30 in controlling apoptosis in
astrocytes under hypoxic stress conditions and in induction of
Figure 3. Insulin-Like Growth Factor I (IGF-I) temporally
decreases microRNA-29b. Total RNA was isolated at various time
points from neuronal cultures treated with IGF-I (100 ng/mL). All RNA
samples were normalized to an internal control, U6 small nuclear RNA.
Analysis was performed in duplicate, with no-template controls.
Relative expression was calculated using the comparative cycle
threshold method (2
2DDCt). Data is expressed as the mean 6 the SE
(n=3). Results were analyzed by one-way ANOVA followed by multiple
comparisons test (** p,0.01, control versus IGF-I treatment).
doi:10.1371/journal.pone.0014724.g003
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pathways as in cardiomyocytes.
Jeyaseelan and colleagues[32] reported that expression of
several miRNA were altered at 24 h and 48 h after reperfusion
in brains of adult rats subjected to transient focal ischemia by
middle cerebral artery occlusion (MCAo). They found that miR-
21 and miR-210 expression are upregulated at 24 h after
reperfusion that is in line with our findings in neurons and
astrocytes exposed to OGD conditions. Similarly, in accord with
our findings, Rendell and colleagues[35] reported upregulation of
miR-21 and miR-30b occurring 24 h after TBI in brain tissue in a
rat model. In line with our findings in cell cultures, Liu and
colleagues[34] also found an increase in expression levels of miR-
107 (at 24 h) in brain tissue of an intraparenchymal hemorrhage
adult rat model, while Rendell[35] reported a downregulation of
miR-107 (at 3, 24, 72 h) in the TBI adult rat model. Differently
from Jeyasselan[32] study in transient ischemia model and our
study in cell cultures subjected to OGD conditions, Liu[34] found
a 1.6 fold downregulation of miR-210 in the hippocampus of a
transient ischemia of MCAo rat model. In his study, Dharap[28]
reported miR-29b (at 3, 6 and 24 h) and miR-137 (at 24 h) to be
downregulated in a MCAo adult rat model, while Lei[33] reported
the same findings in a TBI adult rat model at 6 h post injury.
When comparing our finding of miRNA expression changes in
neuron and astrocyte cell cultures subjected to OGD conditions
with changes reported in brain tissue subjected to ischemic
conditions several considerations need to be made. Most of these
studies were made in adult rat brains. Furthermore some of them
evaluated miRNA expression changes in brain cortex[33], some in
hippocampus[35] and others in the entire brain tissue[32,34]. In
contrast, our experiments were performed on cultures of neurons
and astrocytes prepared from cortex of rat embryos. Studies have
shown that while some miRNAs are expressed during neuronal
differentiation, others are expressed only in mature neu-
rons[41,82] assisting in explaining some of the differences found
between our results in embryonic neurons and astrocytes cultures
and those reported by others in adult brain tissue. Another
consideration to be made is on the differences in the methodol-
ogies used to isolate and detect the different miRNAs. Several
reports and reviews have pointed out the differences that exist
between different microarray platforms that are in use for miRNA
profiling, RT-PCR techniques, and different miRNA isolation kits
in today’s market from different vendors that can interfere with
our ability in comparing our results with other reports[67]. Lastly,
it should not be forgotten that the 3D configuration of the brain
tissue allows for a substantial difference in the communication
between different cells in the space and their influence on each
other, when compared to monolayer cell cultures’ single type cell
interaction.
We have shown here that the induction of changes in miRNA
expression levels is a normal response to ischemia in neurons and
astrocytes and not necessarily only in cancerous and myocardial
cells[7,8,25,74]. We found significant differences in the onset and
magnitude of induction for individual miRNAs in neurons and
astrocytes in response to ischemia. Furthermore, we demonstrate
here that astrocytes and neurons express different miRNAs at
different time-points due to their difference not only in their
miRNA repertoire, but also in their cell specific function within the
CNS. Therefore we suggest that different miRNAs are involved at
different time-points in order for these cells to activate different
biochemical pathways after ischemia to better accomplish their
functions.
In conclusion, our study adds further evidence that hypoxia
induces time-dependent alteration of miRNAs expression levels
suggesting their involvement in the cellular response to ischemic
injury. Furthermore, we provide evidence that in CNS, different
cells activate different miRNAs and at different time-points in
response to ischemic conditions. Other studies that would utilize
the microarray technology could discover other miRNAs that
show expression alteration after OGD in neurons and astrocytes.
Elucidation of the role of miRNAs in ischemia and identification
of their specific targets in astrocytes and neurons warrants further
investigation that may lead to new therapeutical strategies in CNS
injury.
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